Antibodies

11 April 2017

Apogenix Announces Initiation of Clinical Development for ABBV-621 to Treat Solid and Hematologic Tumors by Partner AbbVie

10 April 2017

Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy

10 April 2017

OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept

10 April 2017

OncoMed’s Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint

10 April 2017

Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma

7 April 2017

Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH)

6 April 2017

AnaptysBio Announces First-In-Human Dosing of ANB019

6 April 2017

Affimed Presents Data on Immune Cell Engager Pipeline at the AACR Annual Meeting 2017

6 April 2017

Cascadian Therapeutics Highlights Preclinical Program Presentations at the American Association for Cancer Research Annual Meeting 2017

6 April 2017

MabVax Therapeutics Presents Two Posters at the American Association for Cancer Research (AACR) Annual Meeting on a Novel Radioimmunotherapy Treatment for Pancreatic Cancer

5 April 2017

TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s Anti-PD-L1 Monoclonal Antibody at the American Association for Cancer Research Annual Meeting

5 April 2017

Checkpoint Therapeutics Reports Preclinical Data for Two Oncology Programs

5 April 2017

OSE Immunotherapeutics Presented New Data at AACR* Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells and Inducing Antitumoral Potent T Memory Response

5 April 2017

Immunomedics Reports Sacituzumab Govitecan (IMMU-132) is Active in Patients With Metastatic Small-Cell Lung Cancer Who Are Sensitive or Resistant to First-Line Chemotherapy

5 April 2017

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer

4 April 2017

Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA® (denosumab) To Include Patients With Multiple Myeloma

4 April 2017

Immunomedics Reports Sacituzumab Govitecan (Immu-132) Delivers High Levels of sn-38 That Overcome Chemoresistant Tumors With Moderate to Strong Trop-2 Expression

4 April 2017

Siamab Therapeutics Presents New Preclinical Data for Its Novel Anti-STn Antibodies, Antibody-Drug Conjugates, and Anti-STn Bispecific Antibodies at the AACR Annual Meeting 2017

4 April 2017

Pieris Pharmaceuticals Presents IND-enabling Data for Bispecific Immuno-Oncology Drug Candidate, PRS-343, in Poster Session at the 2017 Meeting of the American Association for Cancer Research (AACR)

4 April 2017

Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical Research

4 April 2017

Bristol-Myers Squibb Announces Results from CheckMate -143, a Phase 3 Study of Opdivo (nivolumab) in Patients with Glioblastoma Multiforme

4 April 2017

OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017

3 April 2017

Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 and DKN-01 at the 2017 AACR Annual Meeting

3 April 2017

Trillium Therapeutics Presents TTI-621 Preclinical Data at AACR Annual Meeting and Provides Clinical Update

3 April 2017

XBiotech Announces Top-Line Results for 514G3 Antibody Therapy in Serious Staphylococcus aureus Infections

3 April 2017

Sutro ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival in Tumor Models

3 April 2017

Aptevo Therapeutics’ Next Generation ADAPTIR™ Bispecific Antibody Candidates Show Potent Immune Activation

3 April 2017

Seattle Genetics Presents Data Advancing Antibody-Drug Conjugate and Novel Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting

3 April 2017

Five-Year Survival Observed With Opdivo (nivolumab) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC), in Phase 1 Study CA209-003

3 April 2017

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) and Opdivo Monotherapy Significantly Improved Overall Survival Versus Yervoy Alone in Patients with Previously Untreated Advanced Melanoma

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Nectin-4-Targeted Immunotherapy Pipeline Review

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Her3-Targeted Immunotherapy Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis